Immunophenotypic profile of peripheral blood eosinophils in acute graft-vs.-host disease.
We used a flow cytometry technique, the "FOG" method (formaldehyde and octylglucopyranoside), to investigate the expression of activation antigens, i.e., CD4, CD23, CD25, HLA-DR, and the EG2 epitope of eosinophilic cationic protein, on peripheral blood eosinophils (PBEs) in leukemic patients who had developed acute graft-vs.-host disease (aGVHD) with eosinophilia after allogeneic bone marrow transplantation (alloBMT) or leukocyte buffy coat infusion. A comparative analysis was performed in transplanted patients not affected by aGVHD and in other conditions commonly associated with peripheral eosinophilia, i.e., interleukin (IL)-2 immunotherapy and allergy. CD25, recognizing the p55 subunit of IL-2 receptor, was detected in all patients with aGVHD except two who, at the onset of eosinophilia, were already receiving methylprednisolone intravenously. The specificity of our findings is confirmed by the absence of reactivity with anti-CD25 mAb in PBEs from transplanted patients not affected by aGVHD. Interestingly, the expression of CD25 progressively declined after steroid therapy. CD25 was also expressed after rhIL-2 administration, probably reflecting analogous mechanisms of eosinophil activation. No aGVHD or rhIL-2-treated patient showed reactivity with anti-CD4, CD23, or HLA-DR. CD25 and CD23 antigens were detected in 29% and 36% of allergic patients only. The accessibility of the EG2 epitope was significantly enhanced in all study groups compared with controls. In vitro activation of normal eosinophils with phorbol 12-myristate 13-acetate upregulated CD9 and EG2 expression but failed to induce the CD25 antigen, suggesting that selective activating stimuli may be required. The functional significance of in vivo CD25 expression and the role of activated PBEs in the development of cellular and cytokine-mediated tissue destructive processes in aGVHD remain to be clarified.
Rumi
C
C
Center for the Flow Cytometric Study of Blood Cells, Catholic University, Rome, Italy.
Rutella
S
S
Bonini
S
S
Bonini
S
S
Lambiase
A
A
Sica
S
S
Puggioni
P
P
Salutari
P
P
Etuk
B
B
Leone
G
G
D000293:Adolescent; D015703:Antigens, CD / Q000032:analysis; D015415:Biomarkers; D016026:Bone Marrow Transplantation / Q000276:immunology*; D015704:CD4 Antigens / Q000032:analysis; D002648:Child; D004802:Eosinophilia / Q000209:etiology / Q000276:immunology / Q000628:therapy; D004804:Eosinophils / Q000276:immunology*; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood* / Q000276:immunology* / Q000517:prevention & control; D006801:Humans; D016130:Immunophenotyping; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000276:immunology / Q000628:therapy*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000276:immunology / Q000628:therapy*; D017455:Receptors, IgE / Q000032:analysis; D015375:Receptors, Interleukin-2 / Q000032:analysis; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors; D014184:Transplantation, Homologous
D015703:Antigens, CD; D015415:Biomarkers; D015704:CD4 Antigens; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D017455:Receptors, IgE; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins